Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

ABSTRACT:

Introduction

This study assesses the effectiveness of durvalumab with platinum and gemcitabine for biliary tract cancers (BTC). It aims to confirm the TOPAZ-1 trial results in a real-world context and explore the link between BTC molecular profiles and patient outcomes.

Methods

A retrospective analysis was conducted on 102 BTC patients treated with durvalumab, platinum, and gemcitabine at five cancer centers in Austria and one in Germany from 2022 to 2024. Molecular profiling used targeted DNA and RNA assays. Clinical endpoints, including progression-free survival (PFS) and overall survival (OS), were assessed using log-rank tests and Cox regression, with correlations to second-line molecular-targeted therapies.

Results

Among 102 patients, 60.8% had intrahepatic chola

SUBMITTER: Reimann P 

PROVIDER: S-EPMC11447177 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature